Figure 9.
Patient-Derived iNSC Therapy for Diffuse GBM Informed by Candidate Quality Marker Expression
(A and B) Summary table (A) and summary plot (b) of candidate marker expression in PF-T and iNSC-Ts, generated from PF-07 and PF-24, predicts that iNSC-7-Ts would have improved potency compared to iNSC-24-Ts. (C) Representative BLI and (D) summary data of GBM-mCFL when iNSC-Ts from either patient was dosed at 4.0 × 105 cells/mouse or 1.0 × 106 cells/mouse (n = 5, ∗∗p < 0.01). (E) Kaplan-Meier survival curves at both doses demonstrating the extension in survival in mice receiving iNSC-Ts from both patients compared to iNSC-GFPs. ∗p < 0.05 and ∗∗p < 0.01 by log-rank test.